Natural Phenomenon or Process

Otsuka’s Phase 3 IgAN Win with Sibeprenlimab Shakes Vera’s Stock

3 days ago talkbio0Tagged IGA Glomerulonephritis, Kidney Diseases, Otsuka, Priority Review, Proteinuria, Sibeprenlimab, stock drop, United States Food and Drug Administration, UPCR, vera

Otsuka; sibeprenlimab; IgA nephropathy; phase 3 trial; proteinuria reduction; Vera Therapeutics; stock drop; kidney disease; UPCR; FDA Priority Review

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

4 days ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study

Schrödinger Lays Off 60 Staffers Amid Economic Uncertainty

3 weeks ago talkbio0Tagged Economic Conditions, Financial cost, layoffs, restructuring, Schrödinger, Transection (procedure)

Schrödinger; layoffs; biotech; workforce reduction; economic conditions; cost cutting; restructuring

Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context

3 weeks ago talkbio0Tagged Droughts, IPO, Market, stocks

biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

4 weeks ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

4 weeks ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

1 month ago talkbio0Tagged Ambulatory Care Facilities, Aortic Valve Insufficiency, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

1 month ago1 month ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

1 month ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader

1 month ago talkbio0Tagged BROADWAY, Cardiovascular Diseases, LDL-C, NewAmsterdam, Obicetrapib, Pooled Sample

Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases